Estimating Cost Savings from Early Cancer Diagnosis

Data

卷:2

Willie Yu¹  Zura Kakushadze²  Rakesh Raghubanshi³ 

[1] Centre for Computational Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore;

[2] Quantigic^® Solutions LLC, 1127 High Ridge Road, 135, Stamford, CT 06905, USA;

[3] Two29 Consulting LLC, 46 Sewell Avenue, Piscataway, NJ 08854, USA;

关键词: cancer;    costs;    incidence;    stage;    early diagnosis;    treatment;    data;   

DOI  :  10.3390/data2030030

来源: DOAJ

【 摘 要 】

We estimate treatment cost-savings from early cancer diagnosis. For breast, lung, prostate and colorectal cancers and melanoma, which account for more than 50% of new incidences projected in 2017, we combine published cancer treatment cost estimates by stage with incidence rates by stage at diagnosis. We extrapolate to other cancer sites by using estimated national expenditures and incidence rates. A rough estimate for the U.S. national annual treatment cost-savings from early cancer diagnosis is in 11 digits. Using this estimate and cost-neutrality, we also estimate a rough upper bound on the cost of a routine early cancer screening test.

【 授权许可】

Unknown